Allovir Inc (ALVR)
$0.78
Live
Insights on Allovir Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 129.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 343.9%
Performance
- $0.77$0.79$0.78
0.91%
Downside
Day's Volatility :2.31%
Upside
1.42%
- $0.62$6.12$0.78
20.12%
Downside
52 Weeks Volatility :89.82%
Upside
87.25%
Returns
| Period | Allovir Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 18.03% | 1.9% | 0.0% |
6 Months | -44.3% | 10.7% | 0.0% |
1 Year | -78.45% | 4.6% | -1.1% |
3 Years | -96.64% | 14.2% | -22.1% |
Highlights
Market Capitalization | 87.6M |
Book Value | $1.32 |
Earnings Per Share (EPS) | -1.83 |
Wall Street Target Price | 1.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -48.44% |
Return On Equity TTM | -102.85% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 165.0K |
EBITDA | -180.9M |
Diluted Eps TTM | -1.83 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.42 |
EPS Estimate Next Year | -0.3 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.16 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 28.21%
Technicals Summary
Sell
Neutral
Buy
Allovir Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Allovir Inc | 4.01% | -44.3% | -78.45% | -96.64% | -96.88% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Allovir Inc | NA | NA | NA | -0.42 | -1.03 | -0.48 | NA | 1.32 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Allovir Inc | Buy | $87.6M | -96.88% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Institutional Holdings
Artal Group S A
5.78%FMR Inc
4.99%Millennium Management LLC
3.42%Wasatch Advisors Inc.
3.32%BlackRock Inc
3.09%Vanguard Group Inc
2.58%
Corporate Announcements
Allovir Inc Earnings
Allovir Inc’s price-to-earnings ratio stands at None
Read More
Company Information
allovir, inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific t cell (vst) therapies to prevent and treat devastating viral-associated diseases. the company's lead product is viralym-m, an allogeneic, off-the-shelf vst therapy, to treat bk virus, cytomegalovirus, adenovirus, epstein-barr virus, and human herpesvirus 6. its preclinical and clinical development product candidates include alvr106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; alvr109 to treat sars-cov-2 and covid-19; alvr107 for treating hepatitis b; and alvr108 to treat human herpesvirus-8, including kaposi's sarcoma, primary effusion lymphoma, and multicentric castleman's diseases. the company was formerly known as viracyte, inc. and changed its name to allovir, inc. in may 2019. allovir, inc. was founded in 2013 and is based in cambridge, massachusetts.
Organization | Allovir Inc |
Employees | 112 |
CEO | Mr. David L. Hallal |
Industry | Health Technology |
